% | $
Quotes you view appear here for quick access.

NovaBay Pharmaceuticals, Inc. Message Board

  • stevefranklin941 Sep 13, 2013 11:17 AM Flag


    An important perspective to keep in mind is that NBY's area of drug development, anti-infectives, has historically been the area with the highest clinical success rate. This is because companies focused on topical anti-microbials, such as NBY, know before they begin the first human clinical trial that their compounds kill the pathogens they are targeting. In NBY's case, they have already confirmed auriclosene's anti-viral capabilities against the adenoviruses that cause conjunctivitis, the staphylococcus aureus and MRSA bacteria implicated in impetigo and also the gram negative Proteus mirabilis bacteria that cause urinary catheter blockage and encrustation. Therefore, success in clinical trials is a matter of safety, concentration, formulation and dosing regimen.

    Sentiment: Strong Buy

0.7354+0.0374(+5.36%)May 27 4:00 PMEDT